Nasus Pharma Ltd (NSRX) Form 10-K Annual Reports
Nasus Pharma Ltd (NSRX) is a publicly traded company on the NYSE, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: NSRX
CIK: 2029039
Exchange: NYSE
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: L3
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Brightman Almagor Zohar & Co.
Auditor SinceSince 12/31/2024 12:00:00 AM
Lead Engagement PartnerEran Dagon
Audit LocationTel Aviv, Israel
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 6-K | 2026-10-08 | 2026-10-08 | 6-K | 0001493152-26-046340 | View SEC Doc Filr Page |
| 3 | 2026-09-23 | 2026-09-19 | 3 | 0001493152-26-043796 | View SEC Doc Filr Page |
| 4 | 2026-09-21 | 2026-09-18 | 4 | 0001493152-26-043559 | View SEC Doc Filr Page |
| 424B5 | 2026-09-18 | — | 424B5 | 0001493152-26-043370 | View SEC Doc Filr Page |
| 6-K | 2026-09-18 | 2026-09-18 | 6-K | 0001493152-26-043342 | View SEC Doc Filr Page |
| 6-K | 2026-09-14 | 2026-09-14 | 6-K | 0001493152-26-042488 | View SEC Doc Filr Page |
| EFFECT | 2026-09-11 | — | EFFECT Filing | 9999999995-26-002954 | View SEC Doc Filr Page |
| 6-K | 2026-09-04 | 2026-09-04 | 6-K | 0001493152-26-041534 | View SEC Doc Filr Page |
| F-3 | 2026-09-01 | — | F-3 | 0001493152-26-041040 | View SEC Doc Filr Page |
| EFFECT | 2026-08-20 | — | EFFECT Filing | 9999999995-26-002715 | View SEC Doc Filr Page |
| 6-K | 2026-08-19 | 2026-08-19 | 6-K | 0001493152-26-039148 | View SEC Doc Filr Page |
| POS AM | 2026-08-19 | — | POS AM | 0001493152-26-039052 | View SEC Doc Filr Page |
| 6-K | 2026-08-17 | 2026-06-30 | 6-K | 0001493152-26-038651 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001172661-26-003431 | View SEC Doc Filr Page |
| 3 | 2026-07-31 | 2026-07-27 | 3 | 0001493152-26-035646 | View SEC Doc Filr Page |
| 4 | 2026-07-29 | 2026-07-22 | 4 | 0001493152-26-035218 | View SEC Doc Filr Page |
| 6-K | 2026-07-28 | 2026-07-28 | 6-K | 0001493152-26-034938 | View SEC Doc Filr Page |
| 4 | 2026-06-22 | 2026-06-17 | 4 | 0001493152-26-029484 | View SEC Doc Filr Page |
| 6-K | 2026-06-09 | 2026-06-09 | 6-K | 0001493152-26-027929 | View SEC Doc Filr Page |
| S-8 | 2026-05-26 | — | S-8 | 0001493152-26-025278 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-05-15 | — | SCHEDULE 13G Filing | 0001193125-26-225115 | View SEC Doc Filr Page |
| 4 | 2026-04-22 | 2026-04-22 | 4 | 0001493152-26-018607 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-04-07 | — | SCHEDULE 13G Filing | 0002073679-26-000045 | View SEC Doc Filr Page |
| 4 | 2026-04-01 | 2026-03-31 | 4 Filing | 0001493152-26-014503 | View SEC Doc Filr Page |
| EFFECT | 2026-03-31 | — | EFFECT Filing | 9999999995-26-001019 | View SEC Doc Filr Page |